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ABSTRACT
The genomes from the organisms of the Plasmodium genus, the causative agents
of human and animal malaria, are characterized by an extreme high A+T content
and an associated abundant low complexity inserts within their proteins. The
enzyme glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (G6PD-
6PGL) found in Plasmodium species has unique structural and bifunctional
characteristics. Here, we report the expression analysis of P. faciparum G6PD-
6PGL along the intraerythrocytic cycle by immunological analysis with antibodies
raised against its N- and C- terminal domains. The pattern modification of band
sizes at the different stages of parasite development suggest intracellular protein
processing involving the cleavage of the native bifunctional form to produce two
main fragments. In vitro RNA-mediated PfG6PD-6PGL gene silencing, studied along
short-term parasite development also revealed the apparent intracellular protein
modification dependent on the parasite stage. Fragment sizes were consistent with
separating both catalytic functions of the enzyme. The proteolytic machinery
underlying this specific PfG6PD-6PGL proccesing is still unknown in P. falciparum
but suggests the existence of distinctive mechanisms in the parasite to deal with
unique protein structures of essential function resulting from its genome evolution.
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RESUMEN
¿Procesamiento de proteínas en Plasmodium falciparum?
Los genomas de los organismos del género Plasmodium, agente causante de la
malaria humana y animal, se caracterizan por un alto contenido en A+T e inser-
ciones de baja complejidad en sus proteínas. La enzima glucosa-6-fosfato deshidro-
genasa-6-fosfogluconolactonasa (G6PD-6PGL) de las especies de Plasmodium posee
unas características estructurales y bifuncionales únicas. En el presente trabajo
analizamos la expresión de la G6PD-6PGL de P. faciparum a lo largo del ciclo
intraeritrocítico mediante análisis inmunológico con anticuerpos frente a sus do-
minios N- y C- terminal. La modificación del tamaño del patrón de bandas en los
diferentes estadios del desarrollo del parásito sugiere un procesamiento intracelu-
lar de la proteína que implicaría que la forma nativa bifuncional genera dos frag-
mentos principales. El silenciamiento in vitro del gen PfG6PD-6PGL, mediante
ARN de interferencia, durante el desarrollo a corto plazo del parásito, también
reveló la aparente modificación intracelular de la proteína dependiente del estadio
de su ciclo vital. El tamaño de los fragmentos fue consistente con la separación de
las dos funciones catalíticas de la enzima. Aunque en P. falciparum no se ha iden-
tificado la maquinaria proteolítica de este procesamiento específico de PfG6PD-
6PGL, nuestros resultados sugieren la existencia de mecanismos especializados
para el procesamiento intracelular de este tipo de proteínas de estructura única y
de función esencial, y que han podido aparecer como consecuencia de la particular
evolución de su genoma.
Palabras clave: Malaria.—Glucosa-6-fosfato deshidrogenasa.—Silenciamiento
de genes.—ARN de interferencia.
INTRODUCTION
Plasmodium falciparum is the causative agent of the most severe
form of human malaria being responsible for the death of more
than 1 million people a year (1). The efforts to control the illness
have been focused on the chemotherapy, mosquito control and in
the development of vaccines. Nowadays, the lack of an effective
vaccine and the increasing parasite resistance to available drugs
suggest the necessity to identify new targets that allow the
development of new drugs and vaccines. Completion of Plasmodium
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genome sequences (2-4) has provided a vast amount of molecular
information. This, together with the transcriptome (5, 6) and
proteomic analysis along the parasitic developmental stages (7)
pursue a deep understanding of the peculiar parasite biology in the
context of exploring new therapeutic and immunization strategies.
Since 1993, different technologies of P. falciparum genetic
manipulation have been developed as gene disruption by homologous
recombination (8-13), antisense RNA (14, 15) and more recently,
RNA interference that has been successfully applied to understand
the in vivo functions of P. falciparum genes (16-18).
Genome comparison from lower eukaryotes have shown that
Plasmodium proteins are notably longer in size than their respective
orthologous genes. This is due to the extraordinary attribute of
Plasmodium proteins that are hugely enriched in stretches biased
toward 1-3 residues (mainly Asn, Lys, and Ile) due to the high A+T
content (about 80% average). Due to this particular composition
these stretches acquire low entropy or complexity (19). These regions
are embedded into highly conserved domains that form globular
structures with larger variety of residue composition with high
entropy and complexity (19). Although many eukaryotes have also
low complexity areas in nuclear proteins, transcription factors,
and some cytoskeletal proteins, Plasmodium species display low
complexity stretches in unique genes, not observed before in genomes
from other organisms. In addition, these unusual regions even
penetrate in independent functional domains with unpredictably
length between 10 and 100 residues (20).
P. falciparum G6PD-6PGL is a bifunctional enzyme exclusive
to Plasmodium species (21) that probably arose from the fusion
of two genes in a common ancestor (22). The deduced protein
has a subunit molecular mass of 107 kDa, in agreement with
the tetramer molecular weight calculated by size exclusion
chromatography (23). Its C-terminal half (residues 311-911) is clearly
homologous to other described G6PDs (with glucose 6-phosphate
dehydrogenase activity) though sequence similarity is interrupted
by a 62 amino-acid stretch with no similarity found to date. It has
been nevertheless experimentally shown that this 62 amino acid
insertion is essential for the activity of the bifunctional enzyme (24).
In contrast, the 310 amino-acid protein sequence of the amino
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terminal region clearly differs from most eukaryotic and prokaryotic
G6PDs, and shows 6-phosphogluconolactonase activity; thus G6PD-
6PGL catalyses the first two stages of the pentose phosphate pathway
(21). The occurrence of large insertion sequences that differ with
respect to their homologous proteins in other species has been often
observed in many gene products of P. falciparum and other
Plasmodium species, but their structural functions and origins are
unknown (24, 25). We have been interested to know whether the low
complexity invasions of globular domains could have a role in
regulating protein turnover along the parasitic cycle, and therefore,
in the present paper, the unique bifunctional P. falciparum G6PD-
6PGL protein was explored as a model gene to study dynamics of its
protein processing along the intraerythrocytic cycle and under gene
silencing conditions.
EXPERIMENTAL PROCEDURES
Parasite cultures and electroporation
P. falciparum strain 3D7 was grown and double synchronised
using standard procedures (26,27). Parasites (ring stage 8-10%
parasitaemia) were transfected by electroporation with 40 µg of
dsRNA as described (8). The parasites transfected with dsRNA-G6PD
or dsRNA-Rab5a were kept for 24 h in 75 cm2 flasks. The growth and
development of each transfection was monitored by Giemsa staining
blood films.
dsRNA design
A 21 basepair dsRNA (sense: UACAUCAUGCACCAACGAAdTdT; antisense:
UUCGUUGGUGCAUGAUGUAdTdT) was designed for the target sequence
(UACAUCAUGCACCAACGAA) of the G6PD-6PGL gene, following Dharmacon
siDESIGN Center criteria (http://design.dharmacon.com/). In
addition, a dsRNA corresponding to the PfRab5a gene (GenBank™
accession number AE001399) (target sequence: UAUGCAAGUAUUGUCCCAC;
sense: UAUGCAAGUAUUGUCCCACdTdT; antisense: GUGGGACAAUACUUGCAUAdTdT)
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was also designed to use as control. All dsRNAs were obtained from
Dharmacon Research (Lafayette, CO, USA) in annealed and
lyophilised form and were suspended in RNase-Dnase-free water
before use.
Immunodetection
Antibodies were raised against two different recombinant
P. falciparum G6PD-6PDL polypeptides expressed in the vector
pGEX (Amersham Biosciences), which contains the glutathione-
S-transferase sequence upstream from the polylinker to produce
a fusion protein with the insert. Sequences from ntG6PD-6PGL
(AAYYICKEIYDKQQINKDGYVVIGLSGGRTPIDVYKNMCLIKDIKIDKSKL)
and ctG6PD-6PGL (KILKSIPSIKLEDTIIGQYEKAENFKEDENNDDESKKNHS)
(see Figure 1 for their location within the G6PD protein) were
amplified and cloned into pGEX. Expression in E. coli was achieved
following the manufacturer’s instructions and the two glutathione-S-
transferase/G6PD-6PDL fusion proteins were separately purified using
a glutathione sepharose affinity column (Amersham Biosciences).
Cleavage of the fusion protein by factor X and subsequent separation
in SDS-PAGE provided pure protein for antibody production.
Antibodies against ntG6PD-6PGL and ctG6PD-6PGL where raised
separately in rabbits but used as a mixture in the Western blot analyses
to increase the signal.
FIGURE 1. G6PD-6PGL protein and location of antibody reactivity. Scheme
showing primary structure of the G6PD-6PGL gene with two main functional
domains, the low complexity stretch (black) and the sequences of the peptides
corresponding to the two antibodies raised (see text).
anti-6PGL-
domain
anti-G6PD-
domain
anti-6PGL domain (AAYYICKEIYDKQQINKDGYVVIGLSGGRTPIDVYKNMCLIKDIKIDKSKL)
anti-G6PD domain (KILKSIPSIKLEDTIIGQYEKAENFKEDENNDDESKKNHS)
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For Western blot analyses, infected red blood cells (IRBCs) from a
10 ml-culture were suspended in 2 volumes of 0.2% saponin in PBS
and incubated for 20 min at 37º C, to lyse the RBC membranes. The
released parasites were pelleted at 10000 x g for 10 min and washed
three times in cold PBS. The parasite pellet was solubilized in 100 μl
of TTP (PBS containing 1% Triton X-100 and a protease inhibitor
cocktail, Complete Mini, Roche Diagnostics, Mannheim, Germany)
and incubated for 30 min at 4º C with frequent vortexing. Next,
the soluble parasite fraction was frozen (at –70º C for 5 min) and
thawed (at 37º C for 5 min) only once and centrifuged for 10 min at
10000 x g. 10 µg of total protein supernatant was boiled in 5x loading
buffer and separated on 10% SDS-PAGE. After electrophoresis,
proteins were transferred to PVDF membranes and probed with the
above mentioned antibodies at 1/200 dilutions. Antibody binding was
detected by incubation with secondary 1/5000 HRP-conjugated sheep
anti-rabbit Ig Abs, followed by chemoluminescence detection using
SuperSignal West Pico (Pierce Biotechnology Inc, Rockford, IL).
Bands were quantified using Quantity One® software (BioRad,
Hercules, CA).
RESULTS
PfG6PD-6PGL protein expression patterns across
the intraeryhrocytic cycle
Expression patterns at the protein level were examined through
immunodetection of parasite G6PD-6PGL using antibodies against
N- and C- terminal separately and a mixture of both of them. Bands
with different molecular weight were consistently observed in
western blots. As shown in Figure 2, a 107 kDa band corresponding
to the theoretical molecular mass of the deduced protein sequence
was abundant mainly in mature stages and detected with both
antibodies. Also two other abundant bands of 73 and 69 KDa were
observed, predominantly in the mature parasite. Thus, the 73 kDa
band, detected by the anti-6PGL domain antibody, has a size that
includes the N-terminal domain with the expected 6PGL activity and
the main low-complexity stretch between both domains. The 69 kDa
band, detected by the anti-G6PD domain antibody, match with the
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expected size of the G6PD domain. In addition, in the mature stages
two other smaller bands were also detected: a 44 kDa band detected
with the anti-6PGL domain and a 39 kDa band detected with the
anti-G6PD domain, which could result from degradation of their
corresponding 73 kDa and 69 kDa band, respectively.
FIGURE 2. G6PD-6PGL protein patterns across the intraerythrocytic cycle of
P. falciparum. Expression patterns at protein level were examined through
immunodetection of the parasite G6PD-6PGL. Parasites harvested at the three
main stages, rings (R), trophozoites (T) and Schizonts (S) were transferred and
immunodeveloped with three different conditions using anti-6PGL domain, anti-
G6PD domain, and a mixture of both of them.
dsRNA silencing of the PfG6PD-6PGL and expression pattern
In an attempt at silencing the G6PD-6PGL gene, erythrocytes
infected with ring-stage P. falciparum 3D7 (pyrimethamine-sensitive
clone) were electroporated with a dsRNA-G6PD duplex, RNase-free
water and dsRNA-Rab5a (the last two as controls) as previously
reported (18).
The G6PD-6PGL protein band pattern during the P. falciparum
intraerythrocyte cycle, as revealed by immunodetection with both
antibodies is shown in Figure 3A. In all stages, two main bands
of different molecular weight were observed, a 107 kDa band
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corresponding to the theoretical molecular mass of the deduced
protein sequence and the 73 kDa band with 2 other subforms in the
mature parasites.
Compared to the control, gene silencing by dsiRNA reduced
G6PD-6PGL immunoreactivity as observed in cultures at 3 and a
24 h (Fig. 3B). Thus, as earlier as 3 h, a 54% and 69% reductions in
the 73 kDa and 107 kDa bands, respectively, were observed (Fig. 3C).
After 24 h, this effect started to diminish, and only 14% and 19%
decreases in the two bands, respectively, were observed (Fig. 3C).
These data confirm previous findings that silencing through dsRNA-
G6PD instantly took place after 3 h of electroporation at the ring
stage, with normal levels gradually restored at the trophozoite stage,
24 h post-transfection (18).
FIGURE 3. Effect of dsRNA on parasite protein levels. (A) Immunoblot analysis
of wild-type synchronized 3D7 rings and trophozoites. The G6PD-6PGL protein
band pattern immunodetected during the intraerythrocyte cycle of P. falciparum
includes the 107, 73, 69 and 53 kDa bands labelled with arrows. (B) Immunoblot
analysis of synchronized wild-type (w) and dsRNA-G6PD transfected (t)
parasites (10 μg of total protein per lane) at 3 and 24 h after electroporation.
(C) Immunoblot quantification of synchronized wild-type and dsRNA-G6PD
parasites. The 107 and 73 kDa bands signal detected were quantified by
densitometry using a Fluor-S MultiImager and Quantity One quantitation
software (Bio-Rad). Value for PfG6PD-6PGL in dsRNA-G6PD parasites is
expressed as a percentage of control levels in wild-type parasites transfected
with water. The positions of molecular mass standards are indicated (kD).
    w    t    w   t
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DISCUSSION
The data presented above indicate that this unique bifunctional
Plasmodium G6PD-6PGL protein varies in size depending on the
parasite developmental stage. Thus, the 69 KDa band detected by
the anti-G6PD domain antibody coincides with the expected size of
the G6PD domain at the C-terminal, and the 73 kDa band identified
by the anti-6PGL domain antibody could have a size that including
the essential insertion (24) corresponds to the N-terminal of the
protein with the 6PGL activity. Thus, it seems that the bifunctional
protein could mature to render two different polypeptides with sepa-
rate enzyme activities but sharing the essential insertion.
To assess specific biological gene function in the parasite, several
systems for the functional analysis of P. falciparum genes have been
developed, including gene silencing by antisense RNA (14, 18) or
more recently, by RNA interference (16-18). Antisense RNA has
been found in humans, mice, plants and protozoan parasites such as
P. falciparum. The fact that endogenous antisense RNAs are
widespread in P. falciparum, suggests that they could be a natural
gene expression regulatory mechanism (28, 29). In our model,
P. falciparum G6PD-6PGL was silenced in vivo through a dsRNA.
Although mechanisms of RNAi silencing in many organisms are not
well known, this technique has been used to study gene function in
a great variety of organisms including other parasites (30). Despite
the fact that, so far, the genes encoding the required RNAi machinary
have not been detected in any of the currently available Plasmodium
databases, RNAi silencing has been achieved in Plasmodium (16-18).
Thus, it could be that the data reported for Plasmodium, as well as
our results using dsRNA-G6PD, are the consequence of an antisense
RNA rather than a direct RNAi effect. However, it is also true that,
to date, 60% of the genes predicted for P. falciparum have no known
homologs, and we have no clues as to their function (4).
The protein expression patterns examined by gene silencing
showed that after 3 h of transfection, when most of the parasites are
at the ring stage, the complete 107 kDa band predominates in both
transfected and not transfected parasites. However, after 24 h of
electroporation when the parasites were mainly at the trophozoite
stage, the main band was the 73 kDa band. Again, this data suggest
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protein size change across parasite life cycle by protein processing
or by alternative splicing. To this respect, different sizes of mRNA
G6PD-6PGL have been observed in parasites in the ring and tropho-
zoite stages (31). Thus, there seems to be specific P. falciparum
mechanisms for processing this mRNA, controlled by the parasite’s
development cycle, which could be unique or shared with other genes
(32, 33). The 69 kDa band could coincide with the C-terminal end of
the protein corresponding to G6PD activity in such a way that it
would not show the N-terminal end that corresponds to the 6PGL
activity. Based on the data shown, we can hypothesize a controlled
pattern of PfG6PD-6PGL processing during parasite maturation as
depicted in Figure 4.
FIGURE 4. Hypothetical processing of G6PD-6PGL. The protein product sizes
observed by immunodetection analysis across the intraerytrocytic P. falciparum life
cycle could be explained by two steps of controlled maturation of the protein to
take apart, optimize and recycle, the two functional enzymatic activities in the
parasite cell.
An independent role of the 6PGL function has been addressed,
and although its 6-phosphogluconolactone substrate is highly
unstable in vitro, some increase in the efficiency of the pathway
may be evident (21,34). To this respect, the lactonase activity
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shown by the bifunctional enzyme is ten times lower than that of
the monofunctional domain 6PGL (21), demonstrating its low
efficiency for 6-phosphogluconolactone hydrolysis. Moreover,
from a structural standpoint, it has also been questioned whether
the bifunctional protein is more efficient in producing NADPH
than two separate enzymes (21). NADPH is also the co-substrate of
Plasmodium glutathione reductase and thioredoxin reductase
enzymes that protects against oxidative stress caused mainly by
digestion of host cell haemoglobin at the late ring-early trophozoite
stage (35). Thus, different NADPH efficiencies could be required
at different developmental stages with particular specialization by
the bifunctional protein (21). Another explanation of this apparent
processing, is the genome economy shown by the small Plasmodium
genome containing a proportionally high number of genes compared
to similar genome sizes (36, 37). Several other unique bifunctional
enzymes have been described in Plasmodium species (38-40)
reflecting the parasite’s rapid evolution in its constant fight to
overcome host defence mechanisms.
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